Exicure (NASDAQ: XCUR) — Perfil da empresa, notícias e dados financeiros
Exicure is focused on developing therapeutics using spherical nucleic acid technology for gene regulation and immunotherapy.

Exicure
Exicure (NASDAQ:XCUR) is a pioneering biotechnology firm deeply engaged in the design and development of therapeutics based on its proprietary spherical nucleic acid (SNA™) technology. These advanced therapeutics have a wide range of applications, including gene regulation and immunotherapy. Exicure's main goal is to harness the power of SNA to unlock new possibilities in the treatment of diseases with genetic origins or for which traditional approaches have been inadequate. The company focuses on advancing its pipeline of innovative treatments through rigorous clinical trials, with the aim of addressing unmet medical needs and improving patient care. By pushing the boundaries of science and technology, Exicure strives to make a significant impact on medicine and healthcare.
Resumo
Operações
Produtos e/ou serviços de Exicure
- Spherical Nucleic Acids (SNA) technology for precision medicine, targeting genetic diseases.
- Development of cavrotolimod (AST-008) as an immuno-oncology therapeutic for solid tumors and lymphomas.
- Collaboration on hair loss treatment focusing on androgenetic alopecia.
- Research into neurological disorder treatments, including Huntington's and Parkinson's diseases.
- Partnerships for dermatological applications of SNA technology, addressing psoriasis and atopic dermatitis.
- Exploration of COVID-19 therapies utilizing proprietary SNA technology.
equipe executiva do Exicure
- Jungsoo KimCEO, President & Director
- Gyuyeob LeeInterim CFO & Secretary
- Young Seung KoChief Operating Officer
- Joshua MillerChief Accounting Officer
- Devki SukhtankarHead of Preclinical Research & Translational Medicine
- Niña CaculitanHead of Clinical
Principais indicadores financeiros
Resultados divulgados pela Exicure, em USD.
- Cap. de mercado
- 6,7 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -10,1 mi | -4,9 mi | |
| 500 mil | -12,2 mi | -9,7 mi | |
| 0 | -15 mi | -16,9 mi | |
| 28,8 mi | -1,8 mi | -2,6 mi |